Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 16, 2025

TORM plc appoints Simon Mackenzie Smith as Chair of the Board

View original at finance.yahoo.com
TORM plc appoints Simon Mackenzie Smith as Chair of the Board INSIDE INFORMATION HELLERUP, Denmark, Dec. 16, 2025 /PRNewswire/ -- TORM plc (Nasdaq: TRMD or TRMD A) is pleased to announce that the Board of Directors has appointed Simon Mackenzie Smith as the new Chair of the Board, succeeding Chris Boehringer…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • I am honored to join TORM and look forward to further strengthening the position of the company. Together, we will focus on delivering long-term value for our customers and shareholders

    80% confidence

  • It has been a pleasure and an honor to serve as Chair of TORM. During this period, TORM has achieved significant long-term value creation for our shareholders, and I am confident that the competencies Simon Mackenzie Smith brings will support the continued development of TORM

    80% confidence

  • TORM has strengthened financial position and continued to develop the One TORM platform, which has been fundamental to continued market-leading performance

    80% confidence

  • The appointment follows a planned process and reflects the Board's strong focus on ensuring continuity and long-term value creation for TORM and shareholders

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com